Safety of Active Immunotherapy in Subjects With Ovarian Cancer

Summary

The purpose of this study is to investigate the safety of the active immune therapy based on the reiterated injection of fully mature, TERT (Telomerase Reverse Transcriptase)-mRNA and Survivin-peptide double loaded DCs (Dendritic Cells) \[Procure®\] in patients with advanced ovarian cancer, enrolled into the study within twelve weeks after completing primary therapy.

Timeline

Start

2010-09

Primary completion

2013-04

Completion

2013-04

Drugs

Indications